Development of commercially viable enantioselective processes for HIV-1 NNRTIs

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 6, 2000, Pages 783-792

  Parsons R L , Jr ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Asymmetric alkynylation; Chiral moderators; Diastereoselective synthesis; HIV 1; Quinazolinones

Indexed keywords

4 (2 CYCLOPROPYLVINYL) 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

CHIRALITY; DISTILLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; REACTION ANALYSIS; REVIEW; STEREOCHEMISTRY;

EID: 0034528608     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Acute human immunodeficiency virus type 1 infection
2. Comparative quantitative structure activity relationship studies on anti-HIV drugs
3. Resistance to antiretroviral drugs - An emerging problem
4. Non-nucleoside inhibitors of HIV-1 reverse tranecriptase
5. L-743726 (DMP 266): A novel highly potent non-nucleoside inhibitor of the human immunodeficiency virus type I reverse transcriptase
6. Synthesis and evaluation of analogs of efavirenz (SUSTIVA(TM)) as HIV-1 reverse transcriptase inhibitors
7. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of efavirenz (SUSTIVA(TM))
8. Expanded-spectrum non-nucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
9. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
10. Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor
11. 3-induced condensation of anilines with nitriles (Sugasawa reaction)
12. Synthesis of the HIV-1 reverse transcriptase inhibitor DMP 266
13. Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
14. Quinazolines and 1,4-benzodiazepines. XXVIII. Substituted 2(3H)-quinazolinones and -quinazolinethiones
15. A new asymmetric 1,4-addition method: Application to the synthesis of the HIV non-nucleoside reverse transcriptase inhibitor DPC 961
16. Uber die einwirkung von phenylsenfol und phenylisocyanat auf isatinsaure
17. Asymmetric synthesis of amines by nucleophilic 1,2-addition of organometallic reagents to the CN-double bond
18. Catalytic enantioselective addition to imines
19. Asymmetric synthesis of α,α-dibranched amines by the trimethylaluminum-mediated 1,2-addition of organolithium to tert-butanesulfinyl ketimines
20. Highly enantioselective transfer of chirality from a less to a more configurationally unstable stereogenic center. A practical asymmetric synthesis of (fluoroalkyl)amines via biomimetic transamination
21. Lithium alkoxides of cinchona alkaloids as chiral controllers for enantioselective acetylide addition to cyclic N-acyl ketimines
22. Lithium ephedrate-mediated addition of a lithium acetylide to a ketone: Solution structures and relative reactivities of mixed aggregates underlying the high enantioselectivities
23. Enantioselective acetylide additions: Practical syntheses of non-nucleoside reverse transcriptase inhibitors
24. Synthesis of amino derivatives of caranol by the addition of cyclic amines to 3-carene oxides
25. An efficient chiral moderator prepared from inexpensive (+)-3-carene: Synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963